VC firms
Gore Range Capital is a venture capital firm focused on hands-on investing in early stage healthcare businesses.
Our approach is simple: we invest in what we know. Over the course of our respective careers, the Gore Range team has built domain expertise and extensive networks across multiple areas of healthcare. Through Gore Range Capital, we are channeling our capabilities to focus on enabling life-long health through investments in skin health, aging, and wellness innovations.
At Gore Range, we blend the hands-on approach of operationally-focused private equity with the early-stage guidance needed in venture capital. We offer not just capital, but insights as well as operational, clinical, and scientific expertise while leveraging our deep industry relationships to position our portfolio companies for success.
Our approach is simple: we invest in what we know. Over the course of our respective careers, the Gore Range team has built domain expertise and extensive networks across multiple areas of healthcare. Through Gore Range Capital, we are channeling our capabilities to focus on enabling life-long health through investments in skin health, aging, and wellness innovations.
At Gore Range, we blend the hands-on approach of operationally-focused private equity with the early-stage guidance needed in venture capital. We offer not just capital, but insights as well as operational, clinical, and scientific expertise while leveraging our deep industry relationships to position our portfolio companies for success.
Overview
Location
United States, New York
Employees
1-10
Founded date
2015
Investment Type
Venture Capital
Investment Stage
Pre-Seed; Seed; Series A
Mentions in press and media 5
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jan 5, 2023 | Palvella Therapeutics Announces Series D Financing of Up to $37.7 Million to Accelerate Late-Stage Development and Support Commercialization of Novel Therapies for Serious, Rare Genetic Skin Diseases | Led by new investor Petrichor, with participation from new and existing investors Lead product candidate, QTORIN™ rapamycin, in late-stage clinical development for serious, rare genetic skin diseases with no FDA-approved therapies Top-line ... |
| Oct 13, 2020 | Gore Range Capital Bolsters Advisory Board for Skin Health Investments | Gore Range Capital, a healthcare venture capital firm, today announced the expansion of its Industry Advisory Board (“IAB”), adding substantial skin health expertise for the launch of Gore Range Capital Fund II (“Fund II”). Joining the IAB ... |
| Oct 13, 2020 | Gore Range Capital Bolsters Advisory Board for Skin Health Investments | Gore Range Capital, a healthcare venture capital firm, today announced the expansion of its Industry Advisory Board (“IAB”), adding substantial skin health expertise for the launch of Gore Range Capital Fund II (“Fund II”). Joining the IAB ... |
| Jan 14, 2019 | Gore Range Closes Debut Healthcare Venture Capital Fund | Gore Range Capital, a New York-based venture capital firm focused on healthcare, closed its first fund to further external capital. Led by Ethan Rigel, CEO, Humberto Antunes, Frank DeBernardis, John Friedman, and Ting-Pau Oei, Gore Range Ca... |
Reviews 0
FAQ about Gore Range Capital
When was Gore Range Capital founded?
Gore Range Capital was founded in 2015.
What has the press written about Gore Range Capital?
Parsers VC has collected 5 articles mentioning Gore Range Capital, among them “Palvella Therapeutics Announces Series D Financing of Up to $37.7 Million to Accelerate Late-Stage Development and Support Commercialization of Novel Therapi...” (Jan 5, 2023) and “Gore Range Capital Bolsters Advisory Board for Skin Health Investments” (Oct 13, 2020).
Is Gore Range Capital still active?
Yes, Gore Range Capital is active; its latest activity on Parsers VC dates from Aug 1, 2024.